Company news: K-V Pharmaceutical and Ther-Rx

Share this article:
In a blow to K-V Pharmaceutical, the FDA said it will not take action against pharmacies that make hydroxyprogesterone caproate, the active ingredient in K-V's recently approved pre-term labor prevention drug Makena. K-V had sent a letter to pharmacists indicating that the agency will no longer allow them to make or compound the injectable drug. “This is not correct,” said FDA in a statement, adding it would not pursue enforcement unless the compounded products are unsafe, of substandard quality or are not compounded according to standards. K-V's branded drug subsidiary Ther-Rx started promoting Makena in March.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.